A Retrospective Study of Safety and Efficacy for Re-treatment of Brentuximab-Vedotin (BV) in Patients With Relapsed/Refractory (R/R) classical Hodgkin Lymphoma (cHL)/ systemic Anaplastic Large-cell Lymphoma (sALCL)
Not Applicable
- Conditions
- CD30 positive cHL or sALC
- Registration Number
- JPRN-UMIN000029982
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
In this study, the efficacy was confirmed of retreatment with brentuximab vedotin in patients with cHL or sALCL who had achieved PR or CR with previous brentuximab vedotin therapy in Japan. AEs in patients with brentuximab vedotin retreatment did not include unexpected AEs and were generally manageable with dose modification or interruption.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients judged by the investigator or subinvestigator to be ineligible for enrollment in the study (such as patients who may be coerced to give consent)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method